Skip to main content

Baker Julian's Form 4 filing

Kodiak Sciences Inc. (KOD) · filed Sep 9, 2021

Accession no.
0001638599-21-000706
Filed
Sep 9, 2021, 6:43 PM ET
Trade date
Sep 7, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $5.37M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Baker JulianCIK 0001087939Director, 10% Owner
Baker FelixCIK 0001087940Director, 10% Owner
Baker Bros. Advisors LPCIK 0001263508Director, 10% Owner
Baker Brothers Life Sciences LPCIK 0001363364Director, 10% Owner
667, L.P.CIK 0001551139Director, 10% Owner
Baker Bros. Advisors (GP) LLCCIK 0001580575Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 7, 2021Common StockPPurchaseAcquired+5,300$92.88F2+$492,279.3713,216,954Indirect
Sep 7, 2021Common StockPPurchaseAcquired+52,201$93.35F6+$4,872,947.6913,269,155Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $92.86 to $92.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $93.00 to $93.92, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Read the full filing on SEC EDGAR (opens in a new tab)